Neurovance, Otsuka deal

Otsuka will acquire Neurovance for $100 million up front and up to $150 million in development and sales milestones. Milestones can be triggered by clinical trial results, development of a once-daily formulation of Neurovance’s centanafadine and regulatory approval of the candidate. The companies expect the deal to close next quarter. Neurovance’s centanafadine SR has completed a Phase IIb study to treat ADHD. The pharma intends to begin a Phase III trial by early next year. ...